What Is Lutetium Psma Therapy?
Lutetium-177 PSMA (abbreviated as 177Lu-PSMA therapy) is a form of radionuclide therapy currently being used in patients with prostate cancer.
Psma Therapy
How Does 177lu-psma Therapy Work?
A small quantity of PSMA (prostate specific membrane antigen) targeting molecule (for eg. PSMA-617, PSMA-I&T etc.) are attached to radioactive Lutetium-177. The PSMA targeting molecule targets the radiation of 177Lu to the prostate cancer target sites. The delivered radiation then kills the cancer cells
How Safe Is 177lu-psma Therapy?
177Lu-PSMA therapy is relatively safe. However, like all treatments it is not free of side effects and benefit of therapy needs to be measured against risk of side effects before giving this treatment. However, overall the side effect profile is quite encouraging, with recent clinical trials suggesting lesser side effects compared to chemotherapy.
What Is the Evidence for 177lu-psma Therapy ?
177Lu-PSMA has the highest level of evidence (randomized phase III clinical trial) proving its effectiveness. This has led to ever increasing interest in and use of 177Lu-PSMA therapy. Recently, the US food and drug administration (FDA) has designated it as a “breakthrough therapy”.
In Which Patients of Prostate Cancer Is Psma Therapy Useful?
PSMA therapy is currently used in patients with metastatic prostate cancer (patients in whom the cancer has spread out of the prostate)